☆ 3.8 Article

Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group

PATIENT-RELATED OUTCOME MEASURES (2023)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group

Mathew S. Maurer et al.

Summary: Immunoglobulin light chain amyloidosis is a rare disease that affects multiple systems in the body. A public-private partnership has been formed to develop new therapies for this disease, with a focus on cardiac endpoints. The review provides recommendations for prioritized cardiovascular endpoints in clinical trials.

CIRCULATION-HEART FAILURE (2022)

Add to Collection

Article Health Care Sciences & Services

Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study

Anita D'Souza et al.

Summary: Interviews with both AL amyloidosis patients and healthcare professionals highlighted the multidimensional impact of the disease on patients' lives, including aspects such as diagnosis, living with the disease, symptom burden, and social roles. Professionals also discussed barriers to collecting patient-reported outcomes data. These themes provide a comprehensive understanding of the experiences of symptom burden in AL amyloidosis patients and offer insight for the development of a clinical outcome assessments tool.

QUALITY OF LIFE RESEARCH (2022)

Add to Collection

Article Oncology

Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change

Anita D'Souza et al.

Summary: In a prospective cohort study of newly diagnosed systemic light chain (AL) amyloidosis patients, patient-reported outcomes (PROs) were found to fluctuate in the first year of treatment, with domains related to 1-year survival including physical function, fatigue, anxiety, depression, and social roles. The study underscores the importance of measuring and tracking PROs in clinical care and research.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

E. Kastritis et al.

Summary: In patients with newly diagnosed AL amyloidosis, adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone resulted in higher rates of hematologic complete response and improved survival outcomes. However, adverse events, including lymphopenia, pneumonia, cardiac failure, and diarrhea, were more common in the daratumumab group. Most deaths were due to amyloidosis-related cardiomyopathy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis

Anita D'Souza et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)

Add to Collection

Review Hematology

High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis

Vaishali Sanchorawala

ACTA HAEMATOLOGICA (2020)

Add to Collection

Article Hematology

Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis

Amanda Schulman et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Review Genetics & Heredity

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis

Isabelle Lousada

ORPHANET JOURNAL OF RARE DISEASES (2020)

Add to Collection

Review Oncology

The Impact of AL Amyloidosis The Patient Experience

Isabelle Lousada et al.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)

Add to Collection

Review Biophysics

High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review

Cindy Varga et al.

BONE MARROW TRANSPLANTATION (2019)

Add to Collection

Article Medicine, General & Internal

A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing

Eli Muchtar et al.

MAYO CLINIC PROCEEDINGS (2019)

Add to Collection

Letter Hematology

Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis

Kristen L. McCausland et al.

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Add to Collection

Article Health Care Sciences & Services

PROMISA (R)-29 v2.0 profile physical and mental health summary scores

Ron D. Hays et al.

QUALITY OF LIFE RESEARCH (2018)

Add to Collection

Article Medicine, General & Internal

Systemic immunoglobulin light chain amyloidosis

Giampaolo Merlini et al.

NATURE REVIEWS DISEASE PRIMERS (2018)

Add to Collection

Article Hematology

Epidemiology of AL amyloidosis: a real-world study using US claims data

Tiffany P. Quock et al.

BLOOD ADVANCES (2018)

Add to Collection

Article Health Care Sciences & Services

Light Chain (AL) Amyloidosis: The Journey to Diagnosis

Kristen L. McCausland et al.

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2018)

Add to Collection

Article Genetics & Heredity

The burden of amyloid light chain amyloidosis on health-related quality of life

Martha Bayliss et al.

ORPHANET JOURNAL OF RARE DISEASES (2017)

Add to Collection

Article Economics

Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report

Katy Benjamin et al.

VALUE IN HEALTH (2017)

Add to Collection

Article Health Care Sciences & Services

Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples

Michelle K. White et al.

PATIENT-RELATED OUTCOME MEASURES (2017)

Add to Collection

Article Hematology

A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time

Vaishali Sanchorawala et al.

BRITISH JOURNAL OF HAEMATOLOGY (2017)

Add to Collection

Review Medicine, General & Internal

Disease burden of systemic light-chain amyloidosis: a systematic literature review

Huamao Mark Lin et al.

CURRENT MEDICAL RESEARCH AND OPINION (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients

Janet Shu et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)

Add to Collection

Article Medicine, Research & Experimental

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium

Isabelle Lousada et al.

ADVANCES IN THERAPY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

The patient's perspective on the symptom and everyday life impact of AL amyloidosis

Huamao Mark Lin et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2015)

Add to Collection

Review Genetics & Heredity

AL Amyloidosis

Estelle Desport et al.

ORPHANET JOURNAL OF RARE DISEASES (2012)

Add to Collection

Article Hematology

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

MA Gertz et al.

AMERICAN JOURNAL OF HEMATOLOGY (2005)

Add to Collection

Article Hematology

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation

DC Seldin et al.

BLOOD (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.